Academic and industry partners from nine different countries join forces to achieve the ambitious goals of the project which has started at the beginning of 2017.
With a lifetime prevalence of over ten percent in the EU, chronic inflammatory disease (CID) poses a major health care burden to modern society. “Our vision is to develop a prediction framework for disease outcome and choice of treatment strategies. With many new targeted therapies coming to the market, we need the right therapy at the right time,” said Professor Philip Rosenstiel from the Institute of Clinical Molecular Biology at Kiel University and scientific coordinator of the SYSCID consortium. “Our approach combines several biomarker layers from the epigenome to the microbiome, but also aims to investigate more sophisticated tools, such as single cell analysis.”
The new epigenetic markers could be more significant than inflammation markers in the blood which have been used so far. As these ‘traditional’ markers also increase in patients with a common cold or elevated temperature, they cannot always be allocated clearly.
SYSCID will use dense clinical sampling and molecular phenotyping to analyse longitudinal patient cohorts and obtain a deeper understanding of the immunological network changes associated with response and non-response to current treatment regimes. Unlike current therapeutic interventions which mainly alleviate the symptoms, SYSCID aims to develop a therapeutic strategy that will eventually offer a first causal therapy. The consortium targets new therapy approaches by ‘reprogramming’ disease through epigenome editing. “Assuming that the development and course of a disease are related to long-term epigenetic alterations, it makes sense to target the very root of the disease,” Rosenstiel said.
SYSCID will build on previous and ongoing research activities by partners and international initiatives such as the International Human Epigenome Consortium (IHEC) with the aim of exploiting already collected and established patient data and enabling their utilisation for the development of new clinical applications. Moreover, the project will create training opportunities and career perspectives for young European scientists with its findings serving as a blueprint for future development of precision medicine in other fields.
Kiel University, Institute of Clinical Molecular Biology
Prof. Dr Philip Rosenstiel
Tel.: +49(0)431/500 15111
Dr. Tebke Böschen
Tel.: +49(431) 880-4682
Project acronym: SYSCID
Start date: 01 January 2017
Duration: 63 months
Budget: € 14.4 Mio
Coordination: Kiel University, Germany
SYSCID Partners at a glance
University of Leuven
University of Southern Denmark
Comma Soft AG
European Research and Project Office GmbH
University of Bonn
Biomedical Research Foundation of the Academy of Athens
University of Luxemburg
University of Geneva
King´s College London
University of Cambridge